{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:14:44Z","timestamp":1794374084699,"version":"4.9.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is rapidly emerging as a transformative approach for treating multiple sclerosis (MS) and other neuroimmune disorders such as neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and myasthenia gravis (MG), alongside several other rare neuroimmunological conditions currently being evaluated in compassionate-use or early-phase studies. These conditions are driven in part by autoreactive B cells that sustain chronic inflammation and progressive tissue damage. While current immunomodulatory therapies have improved clinical outcomes, they often require lifelong administration and fail to effectively eliminate compartmentalized inflammation within the central nervous system. Recent advances in CD19- and BCMA-directed CAR T-cell therapy, initially developed for hematologic malignancies, demonstrate the potential to achieve targeted, durable B-cell depletion and immune reprogramming in autoimmune diseases. Preclinical models and early-phase clinical trials have shown promising efficacy, including reduced relapse rates, stabilization of disability progression, and decreased autoantibody levels, alongside a favorable safety profile with lower rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to oncologic applications. This review synthesizes the current evidence supporting the use of CAR T-cell therapy in neuroinflammatory diseases and explores its potential to redefine treatment paradigms by shifting from chronic immunosuppression to long-term immune tolerance, creating a favorable environment for repair mechanisms. Realizing the full therapeutic promise of CAR T-cells in autoimmune neurology will require sustained research in heterogeneous populations and across disease spectrums.<\/jats:p>","DOI":"10.1186\/s12974-025-03668-0","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:55:02Z","timestamp":1767088502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders"],"prefix":"10.1186","volume":"23","author":[{"given":"Sara","family":"Samadzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Szejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Hamadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Gluscevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito A. G.","family":"Ricigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ECF Young Investigators\/Fellows Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"3668_CR1","doi-asserted-by":"publisher","unstructured":"Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e279.\u00a0https:\/\/doi.org\/10.1212\/NXI.0000000000000279. PMID: 27648465; PMCID: PMC5015541.","DOI":"10.1212\/NXI.0000000000000279"},{"key":"3668_CR2","doi-asserted-by":"publisher","first-page":"175628642110667","DOI":"10.1177\/17562864211066751","volume":"15","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen MB, et al. Smouldering multiple sclerosis: the \u2018real MS\u2019. Ther Adv Neurol Disord. 2022;15:17562864211066751.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"3668_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742\u201368.","journal-title":"Neuron"},{"issue":"9","key":"3668_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3668_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13\u201323.","journal-title":"Ann Neurol"},{"key":"3668_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2015.00636","volume":"6","author":"L Michel","year":"2015","unstructured":"Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-Compartmentalized inflammation. Front Immunol. 2015;6:636.","journal-title":"Front Immunol"},{"key":"3668_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fimmu.2016.00451","volume":"7","author":"M Mitsdoerffer","year":"2016","unstructured":"Mitsdoerffer M, Peters A. Tertiary lymphoid organs in central nervous system autoimmunity. Front Immunol. 2016;7:451.","journal-title":"Front Immunol"},{"key":"3668_CR8","doi-asserted-by":"publisher","unstructured":"Negron A, St\u00fcve O, Forsthuber TG. Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control? Front Neurol. 2020 Dec 8;11:607766. https:\/\/doi.org\/10.1212\/NXI.000000000000027910.3389\/fneur.2020.607766. PMID: 33363512; PMCID: PMC7753025.","DOI":"10.1212\/NXI.000000000000027910.3389\/fneur.2020.607766"},{"issue":"3","key":"3668_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"3668_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"key":"3668_CR11","doi-asserted-by":"publisher","first-page":"103264","DOI":"10.1016\/j.msard.2021.103264","volume":"56","author":"J Correale","year":"2021","unstructured":"Correale J, Halfon MJ, Jack D, Rubstein A, Villa A. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103264.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"3668_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271(4):1515\u201335.","journal-title":"J Neurol"},{"issue":"9","key":"3668_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of Relapse-Independent progression vs Relapse-Associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"key":"3668_CR14","doi-asserted-by":"publisher","unstructured":"Hauser SL, Bar-Or A, Weber MS, Kletzl H, G\u00fcnther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(2):e200094. https:\/\/doi.org\/10.1212\/NXI.0000000000200094. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2023 Mar 27;10(3):e200120. https:\/\/doi.org\/10.1212\/NXI.0000000000200120. PMID: 36792367; PMCID: PMC9931184.","DOI":"10.1212\/NXI.0000000000200094"},{"key":"3668_CR15","doi-asserted-by":"publisher","unstructured":"; Signoriello E, Bonavita S, Di Pietro A, Abbadessa G, Rossi F, Miele G, Casertano S, Lus G. BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord. 2020 Aug;43:102186. https:\/\/doi.org\/10.1016\/j.msard.2020.102186. Epub 2020 May 17. PMID: 32450508.","DOI":"10.1016\/j.msard.2020.102186"},{"key":"3668_CR16","unstructured":"Wexler MECTRIMS. 2025: Standard Ocrevus dose holds up in PPMS Available from: https:\/\/multiplesclerosisnewstoday.com\/ectrims\/2025\/10\/03\/ectrims-2025-standard-ocrevus-dose-holds-ppms\/.\u00a0Accessed date 11 Dec 2025."},{"key":"3668_CR17","doi-asserted-by":"publisher","first-page":"104400","DOI":"10.1016\/j.msard.2022.104400","volume":"68","author":"J Peters","year":"2022","unstructured":"Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"3668_CR18","doi-asserted-by":"publisher","first-page":"e200211","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200211.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"3668_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol. 2022;22(12):734\u201350.","journal-title":"Nat Rev Immunol"},{"key":"3668_CR20","doi-asserted-by":"publisher","first-page":"175628642412330","DOI":"10.1177\/17562864241233041","volume":"17","author":"L Airas","year":"2024","unstructured":"Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, et al. A review of bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis. Ther Adv Neurol Disord. 2024;17:17562864241233041.","journal-title":"Ther Adv Neurol Disord"},{"key":"3668_CR21","doi-asserted-by":"publisher","first-page":"175628641876169","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11:1756286418761697.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"3668_CR22","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev Rep. 2021;17(6):2120\u20133.","journal-title":"Stem Cell Rev Rep"},{"key":"3668_CR23","doi-asserted-by":"publisher","unstructured":"Del Baldo G, Del Bufalo F, Pinacchio C, Carai A, Quintarelli C, De Angelis B, Merli P, Cacchione A, Locatelli F, Mastronuzzi A. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Front Immunol. 2023 Mar 21;14:1142597. https:\/\/doi.org\/10.1016\/j.msard.2020.10218610.3389\/fimmu.2023.1142597. PMID: 37025994; PMCID: PMC10072260.","DOI":"10.1016\/j.msard.2020.10218610.3389\/fimmu.2023.1142597"},{"issue":"11","key":"3668_CR24","doi-asserted-by":"publisher","first-page":"e70298","DOI":"10.1002\/iid3.70298","volume":"13","author":"SY Yao","year":"2025","unstructured":"Yao SY, Du MQ, Yang H, Zeng QM, Zhou H, Zhang X, et al. Chimeric antigen receptor T-Cell therapy and autoimmune diseases in the nervous system. Immun Inflamm Dis. 2025;13(11):e70298.","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"3668_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"2","key":"3668_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of early progression independent of relapse activity with Long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023;80(2):151\u201360.","journal-title":"JAMA Neurol"},{"issue":"8","key":"3668_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"key":"3668_CR28","doi-asserted-by":"crossref","unstructured":"Schett G, Nagy G, Kr\u00f6nke G, Mielenz D. B-cell depletion in autoimmune diseases. Annals of the Rheumatic Diseases. 2024:ard-2024-225727.","DOI":"10.1136\/ard-2024-225727"},{"issue":"7949","key":"3668_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348.","journal-title":"Nature"},{"key":"3668_CR30","doi-asserted-by":"crossref","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci. 1989;86(24):10024\u20138.","DOI":"10.1073\/pnas.86.24.10024"},{"key":"3668_CR31","doi-asserted-by":"publisher","unstructured":"Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, and Function throughout Life. Immunity. 2018 Feb 20;48(2):202-213. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.007. PMID: 29466753; PMCID: PMC5826622.","DOI":"10.1016\/j.immuni.2018.01.007"},{"key":"3668_CR32","doi-asserted-by":"publisher","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012. PMID: 23890059.","DOI":"10.1016\/j.immuni.2013.07.012"},{"issue":"4","key":"3668_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"1","key":"3668_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","volume":"33","author":"BR Dholaria","year":"2019","unstructured":"Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-Cell Therapy-Related toxicities. BioDrugs. 2019;33(1):45\u201360.","journal-title":"BioDrugs"},{"issue":"1","key":"3668_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"3668_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","volume":"13","author":"CL Batlevi","year":"2016","unstructured":"Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"3668_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"5","key":"3668_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","volume":"21","author":"MV Maus","year":"2016","unstructured":"Maus MV, Levine BL. Chimeric antigen receptor T-Cell therapy for the community oncologist. Oncologist. 2016;21(5):608\u201317.","journal-title":"Oncologist"},{"issue":"1","key":"3668_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326.","journal-title":"Immunol Rev"},{"issue":"3","key":"3668_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ana.27029","volume":"96","author":"G Brittain","year":"2024","unstructured":"Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B, et al. The role of chimeric antigen receptor T-Cell therapy in Immune-Mediated neurological diseases. Ann Neurol. 2024;96(3):441\u201352.","journal-title":"Ann Neurol"},{"issue":"2","key":"3668_CR41","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez L, S\u00e1nchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3(2):e186.","journal-title":"Hemasphere"},{"issue":"2","key":"3668_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","volume":"343","author":"XJ Xu","year":"2014","unstructured":"Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343(2):172\u20138.","journal-title":"Cancer Lett"},{"key":"3668_CR43","unstructured":"Cells CART. Engineering patients\u2019 immune cells to treat their cancers was originally published by the National cancer Institute. National Cancer Institute; 2022."},{"issue":"Suppl 3","key":"3668_CR44","first-page":"29","volume":"10","author":"A Beaupierre","year":"2019","unstructured":"Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-Cell therapy. J Adv Pract Oncol. 2019;10(Suppl 3):29\u201340.","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"3668_CR45","first-page":"27","volume":"23","author":"A Beaupierre","year":"2019","unstructured":"Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management across settings: an ambulatory and community perspective for patients undergoing CAR T-Cell therapy in multiple care settings. Clin J Oncol Nurs. 2019;23(2):27\u201334.","journal-title":"Clin J Oncol Nurs"},{"key":"3668_CR46","doi-asserted-by":"publisher","unstructured":"Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol. 2022 Jun 22;10:797440. https:\/\/doi.org\/10.3389\/fbioe.2022.797440. PMID: 35814023; PMCID: PMC9256991.","DOI":"10.3389\/fbioe.2022.797440"},{"issue":"10","key":"3668_CR47","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.3390\/ijms25105361","volume":"25","author":"KS Ku","year":"2024","unstructured":"Ku KS, Tang J, Chen Y, Shi Y. Current advancements in Anti-Cancer chimeric antigen receptor T cell immunotherapy and how nanotechnology May change the game. Int J Mol Sci. 2024;25(10):5361.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"3668_CR48","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene Maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood"},{"issue":"19","key":"3668_CR49","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"1","key":"3668_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"10437","key":"3668_CR51","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024;403(10437):1627\u201330.","journal-title":"Lancet"},{"issue":"5","key":"3668_CR52","doi-asserted-by":"publisher","first-page":"105702","DOI":"10.1016\/j.jbspin.2024.105702","volume":"91","author":"A Guffroy","year":"2024","unstructured":"Guffroy A, Jacquel L, Guffroy B, Martin T. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy. Joint Bone Spine. 2024;91(5):105702.","journal-title":"Joint Bone Spine"},{"issue":"6","key":"3668_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"3668_CR54","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"10","key":"3668_CR55","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3668_CR56","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025;7(2):e83\u201393.","journal-title":"Lancet Rheumatol"},{"issue":"18","key":"3668_CR57","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890\u2013e9049.","journal-title":"Cell"},{"key":"3668_CR58","doi-asserted-by":"publisher","first-page":"1298815","DOI":"10.3389\/fimmu.2023.1298815","volume":"14","author":"L Sheng","year":"2023","unstructured":"Sheng L, Zhang Y, Song Q, Jiang X, Cao W, Li L, et al. Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol. 2023;14:1298815.","journal-title":"Front Immunol"},{"issue":"24","key":"3668_CR59","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154\u201362.","journal-title":"JAMA"},{"issue":"10379","key":"3668_CR60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138.","journal-title":"Lancet"},{"issue":"1","key":"3668_CR61","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, V\u00f6lkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024;63(1):e12\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"10254","key":"3668_CR62","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"10","key":"3668_CR63","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"10416","key":"3668_CR64","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034\u201344.","journal-title":"Lancet"},{"issue":"7","key":"3668_CR65","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3668_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","volume":"44","author":"P G\u00f6del","year":"2018","unstructured":"G\u00f6del P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Understanding cytokine release syndrome. Intensive Care Med. 2018;44(3):371\u20133.","journal-title":"Intensive Care Med"},{"issue":"4","key":"3668_CR67","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3668_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"18","key":"3668_CR69","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"3668_CR70","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"3668_CR71","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood"},{"issue":"3","key":"3668_CR72","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA). Ann Oncol. 2022;33(3):259\u201375.","journal-title":"Ann Oncol"},{"issue":"5","key":"3668_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clinical & Translational Immunology. 2019;8(5):e1049.","journal-title":"Clinical & Translational Immunology"},{"issue":"1","key":"3668_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"2","key":"3668_CR75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"3668_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, V\u00f6lkl S, Aigner M, Bozec A, et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(4):497\u2013504.","journal-title":"Arthritis Rheumatol"},{"key":"3668_CR77","doi-asserted-by":"publisher","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Pappa V, Motte J, Borie D, Gold R, Feist E, Schett G, Mougiakakos D. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. 2024 Oct 21;83(11):1597-1598. https:\/\/doi.org\/10.1136\/ard-2024-226017. PMID: 38937071. .","DOI":"10.1136\/ard-2024-226017"},{"issue":"11","key":"3668_CR78","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, et al. Treatment of concomitant myasthenia Gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron. 2024;112(11):1757\u2013e632.","journal-title":"Neuron"},{"issue":"26","key":"3668_CR79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403227121","volume":"121","author":"S Faissner","year":"2024","unstructured":"Faissner S, Motte J, Sgodzai M, Geis C, Haghikia A, Mougiakakos D, et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci U S A. 2024;121(26):e2403227121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3668_CR80","doi-asserted-by":"publisher","first-page":"e200292","DOI":"10.1212\/NXI.0000000000200292","volume":"11","author":"JM Cabrera-Maqueda","year":"2024","unstructured":"Cabrera-Maqueda JM, Sepulveda M, Garc\u00eda RR, Mu\u00f1oz-S\u00e1nchez G, Mart\u00ednez-Cibrian N, Ort\u00edz-Maldonado V, et al. CD19-Directed CAR T-Cells in a patient with refractory MOGAD. Neurol Neuroimmunol Neuroinflammation. 2024;11(5):e200292.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"8","key":"3668_CR81","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10297","key":"3668_CR82","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"4","key":"3668_CR83","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, del Bufalo F, et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT practice harmonisation and guidelines committee. Lancet Oncol. 2025;26(4):e203\u201313.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3668_CR84","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","volume":"96","author":"FW Vonberg","year":"2025","unstructured":"Vonberg FW, Malik I, O\u2019Reilly M, Hyare H, Carr AS, Roddie C. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. J Neurol Neurosurg Psychiatry. 2025;96(7):665.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3668_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.54","volume":"8","author":"P Berning","year":"2024","unstructured":"Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, et al. Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: a multicenter cohort study. Hemasphere. 2024;8(3):e54.","journal-title":"Hemasphere"},{"key":"3668_CR86","unstructured":"Administration USFaD. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies 2023 Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed date 11 Dec 2025."},{"key":"3668_CR87","unstructured":"Medicine P. 2024 Available from: https:\/\/www.pennmedicine.org\/news\/news-releases\/2024\/january\/secondary-cancers-following-car-t-cell-therapy-are-rare.\u00a0Accessed date 11 Dec 2025."},{"issue":"7","key":"3668_CR88","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2024;390(7):584\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"3668_CR89","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood. 2021;138(9):785\u20139.","journal-title":"Blood"},{"issue":"2","key":"3668_CR90","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"3668_CR91","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139.","journal-title":"Nat Med"},{"key":"3668_CR92","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, Nguyen T, Rahman M, Er J, Li J, Li K, et al. CAR\u2009+\u2009T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 2023;142:6939.","journal-title":"Blood"},{"issue":"2","key":"3668_CR93","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s44321-024-00183-2","volume":"17","author":"P Berg","year":"2025","unstructured":"Berg P, Ruppert-Seipp G, M\u00fcller S, Maurer GD, Hartmann J, Holtick U, et al. CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts. EMBO Mol Med. 2025;17(2):211\u20138.","journal-title":"EMBO Mol Med"},{"key":"3668_CR94","unstructured":"Agency EM. 2024 Available from:\u00a0https:\/\/www.pharmacovigilanceconference.com\/?utm_source=google&utm_medium=cpc&utm_campaign=22300500843&adgroupid=176233452175&keyword=drug%20safety%20conference&gad_source=1&gbraid=0AAAAA9aXZwMH4E9Kbh9sr7HSoj96_a0K5&gclid=CjwKCAjw8IfABhBXEiwAxRHlsIHYYi4oEMiE6py2ncv1cLw9UCXZK92dPZPMu5njqD0-vUJb9pKiehoCgFkQAvDBwE.\u00a0Accessed date 11 Dec 2025."},{"key":"3668_CR95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cyto.2017.02.006","volume":"98","author":"B Matta","year":"2017","unstructured":"Matta B, Song S, Li D, Barnes BJ. Interferon regulatory factor signaling in autoimmune disease. Cytokine. 2017;98:15\u201326.","journal-title":"Cytokine"},{"key":"3668_CR96","doi-asserted-by":"publisher","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA, Dandekar R, Wu GF, Wu W, Pak JE, Hauser SL, Lim W, Wilson MR, Zamvil SS. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 19;10(2):e200080. https:\/\/doi.org\/10.1212\/NXI.0000000000200080. PMID: 36657993; PMCID: PMC9853314.","DOI":"10.1212\/NXI.0000000000200080"},{"issue":"17","key":"3668_CR97","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS. CAR-T efficacy: is conditioning the key? Blood. 2019;133(17):1799\u2013800.","journal-title":"Blood"},{"issue":"6","key":"3668_CR98","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550\u2013e82.","journal-title":"Med"},{"key":"3668_CR99","doi-asserted-by":"publisher","unstructured":"Qin C, Dong MH, Zhou LQ, Chu YH, Pang XW, He JY, Shang K, Xiao J, Zhu L, Ye H, Cai SB, Wang D, Bu BT, Meyer Zu H\u00f6rste G, Li CR, Tian DS, Wang W. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell. 2025 Nov 13;188(23):6414-6423.e11. https:\/\/doi.org\/10.1016\/j.cell.2025.09.020. Epub 2025 Oct 15. PMID: 41101309.l .","DOI":"10.1016\/j.cell.2025.09.020"},{"key":"3668_CR100","doi-asserted-by":"publisher","unstructured":"Kim SH, Jang H, Park NY, Kim Y, Kim SY, Lee MY, Hyun JW, Kim HJ. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):e947. https:\/\/doi.org\/10.1212\/NXI.0000000000000947. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2021 Apr 19;8(4):e1013. https:\/\/doi.org\/10.1212\/NXI.0000000000001013. PMID: 33622675; PMCID: PMC7903808.","DOI":"10.1212\/NXI.0000000000000947"},{"issue":"12","key":"3668_CR101","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","volume":"267","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267(12):3565\u201377.","journal-title":"J Neurol"},{"issue":"1","key":"3668_CR102","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, H\u00e4u\u00dfler V, et al. Update on the diagnosis and treatment of neuromyelitis Optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis Optica study group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"1","key":"3668_CR103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian D-S, Zhou L-Q, Shang K, Huang L, Dong M-H, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis Optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Therapy. 2023;8(1):5.","journal-title":"Signal Transduct Target Therapy"},{"issue":"7","key":"3668_CR104","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia Gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3668_CR105","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(23)00211-9","volume":"22","author":"A Meisel","year":"2023","unstructured":"Meisel A. Are CAR T cells the answer to myasthenia Gravis therapy? Lancet Neurol. 2023;22(7):545\u20136.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3668_CR106","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia Gravis. Lancet Neurol. 2023;22(12):1104\u20135.","journal-title":"Lancet Neurol"},{"issue":"11","key":"3668_CR107","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.xcrm.2024.101794","volume":"5","author":"J Wickel","year":"2024","unstructured":"Wickel J, Schnetzke U, Sayer-Klink A, Rinke J, Borie D, Dudziak D, et al. Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med. 2024;5(11):101794.","journal-title":"Cell Rep Med"},{"key":"3668_CR108","doi-asserted-by":"crossref","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, et al. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells. Neuron. 2024;112(11):1757-63.e2.","DOI":"10.1016\/j.neuron.2024.04.014"},{"issue":"2","key":"3668_CR109","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jcyt.2024.09.008","volume":"27","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, et al. Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. Cytotherapy. 2025;27(2):236\u201346.","journal-title":"Cytotherapy"},{"issue":"6","key":"3668_CR110","doi-asserted-by":"publisher","first-page":"e200479","DOI":"10.1212\/NXI.0000000000200479","volume":"12","author":"I Ayzenberg","year":"2025","unstructured":"Ayzenberg I, Aloizou AM, Lohmann C, Faissner S, Schneider-Gold C, Borie D, et al. Anti-CD19 CAR T-Cell therapy in advanced Stiff-Person syndrome and concomitant myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm. 2025;12(6):e200479.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"3668_CR111","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-Cell analyses identify brain mural cells expressing CD19 as potential Off-Tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126\u2013e4217.","journal-title":"Cell"},{"issue":"4","key":"3668_CR112","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019. Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"3668_CR113","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925\u201335.","journal-title":"Blood"},{"issue":"3","key":"3668_CR114","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1017\/cjn.2022.60","volume":"50","author":"P Kanatas","year":"2023","unstructured":"Kanatas P, Stouras I, Stefanis L, Stathopoulos P, B-Cell-Directed. Therapies: A new era in multiple sclerosis treatment. Can J Neurol Sci. 2023;50(3):355\u201364.","journal-title":"Can J Neurol Sci"},{"key":"3668_CR115","doi-asserted-by":"crossref","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12(19).","DOI":"10.3390\/jcm12196124"},{"issue":"5","key":"3668_CR116","doi-asserted-by":"publisher","first-page":"e200292","DOI":"10.1212\/NXI.0000000000200292","volume":"11","author":"JM Cabrera-Maqueda","year":"2024","unstructured":"Cabrera-Maqueda JM, Sepulveda M, Garc\u00eda RR, Mu\u00f1oz-S\u00e1nchez G, Mart\u00ednez-Cibrian N, Ort\u00edz-Maldonado V, Lorca-Arce D, Guasp M, Llufriu S, Martinez-Hernandez E, Armangue T, Fonseca EG, Alba-Isasi MT, Delgado J, Dalmau J, Juan M, Saiz A, Blanco Y. CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200292. https:\/\/doi.org\/10.1212\/NXI.0000000000200292. Epub 2024 Aug 6. PMID: 39106426; PMCID: PMC11309560.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"3668_CR117","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","volume":"16","author":"DS Tian","year":"2024","unstructured":"Tian DS, Qin C, Dong MH, Heming M, Zhou LQ, Wang W, et al. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia Gravis. EMBO Mol Med. 2024;16(4):966\u201387.","journal-title":"EMBO Mol Med"},{"issue":"3\u20134","key":"3668_CR118","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.seminoncol.2024.02.001","volume":"51","author":"MR Bishop","year":"2024","unstructured":"Bishop MR, Kay GE. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. Semin Oncol. 2024;51(3\u20134):87\u201394.","journal-title":"Semin Oncol"},{"issue":"95","key":"3668_CR119","doi-asserted-by":"publisher","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","volume":"9","author":"C Qin","year":"2024","unstructured":"Qin C, Zhang M, Mou DP, Zhou LQ, Dong MH, Huang L, et al. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci Immunol. 2024;9(95):eadj9730.","journal-title":"Sci Immunol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03668-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03668-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03668-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:04:47Z","timestamp":1769519087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03668-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3668"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03668-0","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}